Cargando…

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyamoto, Kenichi, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404220/
https://www.ncbi.nlm.nih.gov/pubmed/32698349
http://dx.doi.org/10.3390/ijms21145114
_version_ 1783567104848429056
author Miyamoto, Kenichi
Minami, Yosuke
author_facet Miyamoto, Kenichi
Minami, Yosuke
author_sort Miyamoto, Kenichi
collection PubMed
description Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML.
format Online
Article
Text
id pubmed-7404220
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74042202020-08-11 Cutting Edge Molecular Therapy for Acute Myeloid Leukemia Miyamoto, Kenichi Minami, Yosuke Int J Mol Sci Review Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML. MDPI 2020-07-20 /pmc/articles/PMC7404220/ /pubmed/32698349 http://dx.doi.org/10.3390/ijms21145114 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miyamoto, Kenichi
Minami, Yosuke
Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title_full Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title_fullStr Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title_full_unstemmed Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title_short Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
title_sort cutting edge molecular therapy for acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404220/
https://www.ncbi.nlm.nih.gov/pubmed/32698349
http://dx.doi.org/10.3390/ijms21145114
work_keys_str_mv AT miyamotokenichi cuttingedgemoleculartherapyforacutemyeloidleukemia
AT minamiyosuke cuttingedgemoleculartherapyforacutemyeloidleukemia